Home » Stocks » MGTA

Magenta Therapeutics, Inc. (MGTA)

Stock Price: $11.36 USD 0.82 (7.78%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 552.13M
Revenue (ttm) n/a
Net Income (ttm) -74.94M
Shares Out 43.92M
EPS (ttm) -1.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $11.36
Previous Close $10.54
Change ($) 0.82
Change (%) 7.78%
Day's Open 10.88
Day's Range 10.75 - 11.59
Day's Volume 150,565
52-Week Range 6.03 - 14.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

2 weeks ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

1 month ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more pat...

2 months ago - Business Wire

This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.

2 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset vi...

2 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset vi...

3 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

4 months ago - Business Wire

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, KLDO
4 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more pati...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145...

Other stocks mentioned: BLUE
5 months ago - Business Wire

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: APRN, CACC, CLH, LOGC
5 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

5 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

6 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more pati...

6 months ago - Business Wire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADT, FTI, FLY, NEX
7 months ago - 24/7 Wall Street

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

7 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more pati...

8 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

9 months ago - Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, to...

9 months ago - Business Wire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AXLA, CTMX, KLDO
9 months ago - 24/7 Wall Street

Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

10 months ago - Business Wire

The company announced the pricing of a public offering of common stock.

10 months ago - The Motley Fool

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

10 months ago - Business Wire

NEW YORK, June 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ: MGTA). Such investors are advised...

10 months ago - PRNewsWire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to mor...

10 months ago - Business Wire

NEW YORK, June 15, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Magenta Therapeutics, Inc. ("Magenta" or t...

10 months ago - PRNewsWire

As of late, it has definitely been a great time to be an investor in Magenta Therapeutics.

10 months ago - Zacks Investment Research

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Other stocks mentioned: ARGX, BLUE, BPMC, EPZM, FATE
1 year ago - 24/7 Wall Street

New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.

Other stocks mentioned: MTEM
1 year ago - The Motley Fool

Magenta Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Shares have risen by around 25% since my initial article.

1 year ago - Seeking Alpha

Can you guess what these high-flying stocks have in common?

Other stocks mentioned: AXSM, PHAS
2 years ago - The Motley Fool

About MGTA

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to bring the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The company is developing C100 and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of g... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Jason Gardner
Employees
69
Stock Exchange
NASDAQ
Ticker Symbol
MGTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for MGTA stock is "Strong Buy." The 12-month stock price forecast is 18.33, which is an increase of 61.36% from the latest price.

Price Target
$18.33
(61.36% upside)
Analyst Consensus: Strong Buy